Atlas Trials

Efficacy and Safety of Trastuzumab Biosimilars and Pertuzumab Biosimilars Combined With Chemotherapy for Neoadjuvant Treatment of Patients With Locally Advanced HER2-positive Rectal Cancer

Clinical trial NCT07108127 · RECRUITING

Trial details

NCT number
NCT07108127
Sponsor
Peking Union Medical College Hospital
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Rectal CancerHER2-positive
Start date
2025-06-20
Primary completion
2026-12-01
Enrollment
24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.